UNSPSC 85761379: Alteration of abdominal wall with nonautologous tissue substitute, percutaneous approach

This classification denotes the group of activities that yields a surgical intervention or procedure to alteration of abdominal wall with nonautologous tissue substitute, percutaneous approach. This surgical intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 0W0F3KZ

UNSPSC 85761379, Alteration of abdominal wall with nonautologous tissue substitute, percutaneous approach, is a Commodity code that does not align with recent state and local procurement activity. The source contains six recent opportunities posted between July and September 2026, none of which involve surgical procedures, tissue substitutes, or abdominal wall alteration. The opportunities span independent medical evaluation services for disability retirement determinations (City of Phoenix Retirement Office), surgical carve-out benefit programs for employee health plans (City of Long Beach), occupational medical surveillance for state ferry workers (Washington State Department of Transportation), emergency and specialty medical services for detained youth (Harris County Juvenile Probation Department), pharmacy benefit management administration (Collier County Board of County Commissioners), and temporary ancillary health professional staffing (County of Santa Clara Health System). None of these solicitations involve the procedural or supply scope implied by the code's title.

The mismatch between the code and the recent opportunities suggests either misclassification of the opportunities at posting or very limited procurement activity under this code at the state and local level. No representative solicitations directly relevant to abdominal wall procedures with nonautologous tissue substitutes appear in the recent opportunities block. State and local procurement under this code should be monitored for future activity, but current evidence does not support active pursuit based on the available market signals.